Divergent Preferences for HIV Prevention : A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa
BACKGROUND: The development of antiretroviral (ARV)-based prevention products has the potential to substantially change the HIV prevention landscape; yet, little is known about how appealing these products will be outside of clinical trials, as compared with the existing options.
METHODS: We conducted a discrete choice experiment (DCE) to measure preferences for 5 new products among 4 important populations in the HIV response: adult men and women in the general population (aged 18 to 49 y), adolescent girls (aged 16 to 17 y), and self-identifying female sex workers (aged 18 to 49 y). We interviewed 661 self-reported HIV-negative participants in peri-urban South Africa, who were asked to choose between 3 unique, hypothetical products over 10 choice sets. Data were analyzed using multinomial, latent class and mixed multinomial logit models.
RESULTS: HIV protection was the most important attribute to respondents; however, results indicate significant demand among all groups for multipurpose prevention products that offer protection from HIV infection, other STIs, and unwanted pregnancy. All groups demonstrated a strong preference for long-lasting injectable products. There was substantial heterogeneity in preferences within and across population groups.
LIMITATIONS: Hypothetical DCE data may not mirror real-world choices, and products will have more attributes in reality than represented in choice tasks. Background data on participants, including sensitive areas of HIV status and condom use, was self-reported.
CONCLUSIONS: These results suggest that stimulating demand for new HIV prevention products may require a more a nuanced approach than simply developing highly effective products. No single product is likely to be equally attractive or acceptable across different groups. This study strengthens the call for effective and attractive multipurpose prevention products to be deployed as part of a comprehensive combination prevention strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Medical decision making : an international journal of the Society for Medical Decision Making - 38(2018), 1 vom: 01. Jan., Seite 120-133 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quaife, Matthew [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.02.2019 Date Revised 15.02.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/0272989X17729376 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275359778 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275359778 | ||
| 003 | DE-627 | ||
| 005 | 20231225005510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0272989X17729376 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0917.xml |
| 035 | |a (DE-627)NLM275359778 | ||
| 035 | |a (NLM)28863752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quaife, Matthew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Divergent Preferences for HIV Prevention |b A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2019 | ||
| 500 | |a Date Revised 15.02.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The development of antiretroviral (ARV)-based prevention products has the potential to substantially change the HIV prevention landscape; yet, little is known about how appealing these products will be outside of clinical trials, as compared with the existing options | ||
| 520 | |a METHODS: We conducted a discrete choice experiment (DCE) to measure preferences for 5 new products among 4 important populations in the HIV response: adult men and women in the general population (aged 18 to 49 y), adolescent girls (aged 16 to 17 y), and self-identifying female sex workers (aged 18 to 49 y). We interviewed 661 self-reported HIV-negative participants in peri-urban South Africa, who were asked to choose between 3 unique, hypothetical products over 10 choice sets. Data were analyzed using multinomial, latent class and mixed multinomial logit models | ||
| 520 | |a RESULTS: HIV protection was the most important attribute to respondents; however, results indicate significant demand among all groups for multipurpose prevention products that offer protection from HIV infection, other STIs, and unwanted pregnancy. All groups demonstrated a strong preference for long-lasting injectable products. There was substantial heterogeneity in preferences within and across population groups | ||
| 520 | |a LIMITATIONS: Hypothetical DCE data may not mirror real-world choices, and products will have more attributes in reality than represented in choice tasks. Background data on participants, including sensitive areas of HIV status and condom use, was self-reported | ||
| 520 | |a CONCLUSIONS: These results suggest that stimulating demand for new HIV prevention products may require a more a nuanced approach than simply developing highly effective products. No single product is likely to be equally attractive or acceptable across different groups. This study strengthens the call for effective and attractive multipurpose prevention products to be deployed as part of a comprehensive combination prevention strategy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a HIV prevention | |
| 650 | 4 | |a South Africa | |
| 650 | 4 | |a discrete choice experiments | |
| 650 | 4 | |a key populations | |
| 650 | 4 | |a pre-exposure prophylaxis | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Eakle, Robyn |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrera Escobar, Maria A |e verfasserin |4 aut | |
| 700 | 1 | |a Vickerman, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kilbourne-Brook, Maggie |e verfasserin |4 aut | |
| 700 | 1 | |a Mvundura, Mercy |e verfasserin |4 aut | |
| 700 | 1 | |a Delany-Moretlwe, Sinead |e verfasserin |4 aut | |
| 700 | 1 | |a Terris-Prestholt, Fern |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical decision making : an international journal of the Society for Medical Decision Making |d 1993 |g 38(2018), 1 vom: 01. Jan., Seite 120-133 |w (DE-627)NLM012875996 |x 1552-681X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2018 |g number:1 |g day:01 |g month:01 |g pages:120-133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/0272989X17729376 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2018 |e 1 |b 01 |c 01 |h 120-133 | ||